There is a lack of robust evidence to assess the strength of other treatment options
Objectives Sarcopenia , defined as an age-associated loss of skeletal muscle function and muscle mass , occurs in approximately 6 - 22 % of older adults .
This paper presents evidence -based clinical practice guidelines for screening , diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research ( ICSFR ) .
Treatment of sporadic inclusion body myositis with bimagrumab
Objective : To study activin signaling and its blockade in sporadic inclusion body myositis ( sIBM ) through translational studies and a r and omized controlled trial . Methods : We measured transforming growth factor β signaling by SMAD2/3 phosphorylation in muscle biopsies of 50 patients with neuromuscular disease ( 17 with sIBM ) . We tested inhibition of activin receptors IIA and IIB ( ActRII ) in 14 patients with sIBM using one dose of bimagrumab ( n = 11 ) or placebo ( n = 3 ) . The primary outcome was the change in right thigh muscle volume by MRI at 8 weeks . Lean body mass , strength , and function were secondary outcomes . Twelve of the patients ( 10 bimagrumab , 2  placebo )  participated in a subsequent 16-week observation phase . Results : Muscle SMAD2/3 phosphorylation was higher in sIBM than in other muscle diseases studied ( p = 0.003 ) . Eight weeks after dosing , the bimagrumab-treated patients increased thigh muscle volume ( right leg + 6.5 % compared with placebo , p = 0.024 ; left leg + 7.6 % , p = 0.009 ) and lean body mass ( + 5.7 % compared with placebo , p = 0.014 ) . Subsequently , bimagrumab-treated patients had improved 6-minute walking distance , which peaked at 16 weeks ( + 14.6 % , p = 0.008 ) compared with placebo . There were no serious adverse events ; the main adverse events with bimagrumab were mild acne and transient involuntary muscle contractions . Conclusions : Transforming growth factor β superfamily signaling , at least through ActRII , is implicated in the pathophysiology of sIBM . Inhibition of ActRII increased muscle mass and function in this pilot trial , offering a potential novel treatment of sIBM . Classification of evidence : This study provides Class I evidence that for patients with inclusion body myositis  , bimagrumab increases thigh muscle volume at 8 weeks
There is a lack of robust evidence to assess the strength of other treatment options
Objectives Sarcopenia , defined as an age-associated loss of skeletal muscle function and muscle mass , occurs in approximately 6 - 22 % of older adults .
This paper presents evidence -based clinical practice guidelines for screening , diagnosis and management of sarcopenia from the task force of the International Conference on Sarcopenia and Frailty Research ( ICSFR ) .